Adaptimmune Therapeutics PLC · OTC:ADAPY
Adaptimmune Therapeutics — Investor Presentation (March 2017)
31 slides from Adaptimmune Therapeutics's investor presentation, Mar 14, 2017
Slide 1: Disclaimer
Disclaimer This presentation contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “believe,” “may”, “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and o
Slide 2: Adaptimmune: Leading the TCR T-cell Space
Adaptimmune: Leading the TCR T-cell Space Pioneering Peerless Industry leading Transformative Data driven Forward-thinking 24 years of TCR innovation The only affinity- tuned TCRs Unmatched SPEAR® T-cell pipeline Proven efficacy in solid tumors Informed approach to clinical development Combination a
Slide 3: Nearly all proteins are available to TCRs
Nearly all proteins are available to TCRs Unlimited targets; utilizes the T-cell’s native receptor Affinity tuned SPEAR TCRs overcome low target expression; required to address solid tumors Access to extra- and intracellular proteins CAR-T vs TCR: Differences in Access to Human Proteome TCRs CAR-T S
Slide 4: Affinity Optimization is Critical to Address Majority of Antigens
Affinity Optimization is Critical to Address Majority of Antigens Adaptimmune is the Only Company with this Proprietary Technology T-cells bind to targets on cancer cells Cancer downregulates targets to avoid detection Most naturally occurring anti-tumor T-cells are low affinity (require more target
Slide 5: Developing Novel TCR Therapies Utilizing Proprietary Technology Platform
Developing Novel TCR Therapies Utilizing Proprietary Technology Platform to Develop Multiple Approaches Cancer Testis Antigens Exclusive to tumor tissue; shown to be good targets But expressed less frequently across cancers Developing a franchise with overlapping expression profiles Examples: NY-ESO
Slide 6: Adaptimmune Pipeline Overview
Adaptimmune Pipeline Overview Multiple Targets with Near Term Clinical Milestones Clinical data in synovial sarcoma and multiple myeloma Active trials in synovial sarcoma, MRCLS, ovarian and non-small cell lung cancer (NSCLC) Upcoming registration studies in synovial sarcoma NY-ESO IND open Studies
Slide 7: Adaptimmune Pipeline Overview
Adaptimmune Pipeline Overview Multiple Targets with Near Term Clinical Milestones * Clinical data in synovial sarcoma and multiple myeloma fesk] * Active trials in synovial sarcoma, MRCLS, ovarian NEES and non-small cell lung cancer (NSCLC) * Upcoming registration studies in synovial GSK option sarc
Slide 8: Deep Pipeline Across Major Cancers: NY-ESO Sarcoma
Deep Pipeline Across Major Cancers NY-ESO SPEAR T-cell Development Program: Sarcoma SPEAR target Indication Notes Pre-IND Phase I / II Registration NY-ESO Synovial sarcoma Registration Cohort 1 - High NY-ESO +CTX / FLU Cohort 2 - Low NY-ESO +CTX / FLU Cohort 3 – no fludarabine Cohort 4 – modified CT
Slide 9: NY-ESO SPEAR T-cell Development Program: Multiple Myeloma
2017/2018 Milestones: Initiation of combination study with KEYTRUDA®; potential for data in late 2017 Deep Pipeline Across Major Cancers NY-ESO SPEAR T-cell Development Program: Multiple Myeloma SPEAR target Indication Notes Pre-IND Phase I / II Registration NY-ESO Multiple myeloma Autologous SCT Co
Slide 10: NY-ESO Programs: Ovarian, Melanoma, and NSCLC
2017/2018 Milestones: Data from studies in NSCLC and ovarian (with FLU) Deep Pipeline Across Major Cancers NY-ESO SPEAR T-cell Development Programs: Ovarian, Melanoma, and NSCLC Results of ovarian and melanoma studies with CTX only highlight need for preconditioning regimen including fludarabine SPE
Slide 11: Frequency of Grade 3+ CRS: NY-ESO SPEAR-T vs CAR-Ts
Frequency of Grade 3+ CRS: NY-ESO SPEAR-T vs CAR-Ts Adaptimmune NY-ESO SPEAR T-cell therapy 8.6% No Grade 5 CRS All cases resolved 18% CD19 CAR-T in DLBCL/PMBCL 27% 23% 39% JCAR 017 CAR-T in Pediatric ALL JCAR 014 CAR-T in Adult ALL JCAR 015 CAR-T in ALL 8% 10% JCAR 014 CAR-T in CLL JCAR 014 CAR-T i
Slide 12: Neurotoxicity: NY-ESO SPEAR-T vs CAR-Ts
Neurotoxicity: NY-ESO SPEAR-T vs CAR-Ts NY-ESO SPEAR T-cells: Not associated with the type and severity of neurotoxicity events seen with CAR-T 34% Grade 3 or 4 3% Grade 5 CD19 CAR-T in DLBCL/PMBCL 23% Severe JCAR 017 CAR-T in Pediatric ALL JCAR 014 CAR-T in Adult ALL JCAR 015 CAR-T in ALL JCAR 014
Slide 13: MAGE-A10 and -A4: Expressed Across a Wide Range of Tumors
Deep Pipeline Across Major Cancers MAGE-A10 and -A4: Expressed Across a Wide Range of Tumors MAGE-A10 Expression MAGE-A4 Expression US1 Europe2 Urothelial 16,390 52,374 Head and neck 9,570 43,704 Ovarian 14,240 42,716 Melanoma 10,130 22,199 Lung 158,080 353,580 Esophageal 15,690 39,504 Gastric 10,73
Slide 14: MAGE-A10 and -A4 SPEAR T-cell Development Programs
Deep Pipeline Across Major Cancers MAGE-A10 and -A4 SPEAR T-cell Development Programs: Multiple Cancers SPEAR target Indication Notes Pre-IND Phase I / II Registration MAGE-A10 Non-small cell lung cancer (NSCLC) modified CTX / FLU Urothelial (bladder), melanoma, H&N modified CTX / FLU MAGE-A4 Urothe
Slide 15: Building a Franchise: Broad Coverage of Cancers
Deep Pipeline Across Major Cancers Building a Franchise: Broad Coverage of Cancers with Existing CTA Pipeline Lung Squamous Cell NY-ESO-1 22% MAGE-A10 33% MAGE-A4 60% Expression by 1 or more 65% Head & Neck Cancer (squamous cell) NY-ESO-1 10% MAGE-A10 14% MAGE-A4 42% Expression by 1 or more 44% Tumo
Slide 16: AFP SPEAR T-cell Development Program: Hepatocellular cancer
Deep Pipeline Across Major Cancers AFP SPEAR T-cell Development Program: Hepatocellular cancer SPEAR target Indication Notes Pre-IND Phase I / II Registration AFP Hepatocellular cancer Modified CTX / FLU AFP Expression US1 Europe2 Liver HCC 27,170 62,152 2017/2018 Milestones: Data from study in hepa
Slide 17: Unmatched Clinical Pipeline of Affinity Enhanced TCRs
Unmatched Clinical Pipeline of Affinity Enhanced TCRs SPEAR target Indication Notes Pre-IND Phase I / II Registration trial NY-ESO Synovial sarcoma Registration trial Cohort 1 - High NY-ESO + CTX / FLU Cohort 2 - Low NY-ESO + CTX / FLU Cohort 3 – no FLU Cohort 4 – modified CTX / FLU Myxoid / Round c
Slide 18: 2017: A Year of Significant Data Delivery
2017: A Year of Significant Data Delivery Potential for Data from Multiple SPEAR T-cell Therapies in 2017 and 2018 NY-ESO Synovial Sarcoma Cohorts 1, 2, and 4 MRCLS Multiple Myeloma + KEYTRUDA Ovarian + Flu NSCLC MAGE-A10 NSCLC Urothelial (bladder), melanoma, H&N MAGE-A4 Urothelial, melanoma, H&N, o
Slide 19: Beyond the Clinical Pipeline
Beyond the Clinical Pipeline 20
Slide 20: Next Generation: Depth and Durability in Solid Tumors
Leading Innovation in Engineered T-cell Therapy Next Generation: Depth and Durability in Solid Tumors Combination studies starting in 2017 Enhancing resistance to tumor microenvironment: 5 programs and growing Enhancing T-cell potency and function: 11 programs and growing Enhancement of Class-I rest
Slide 21: Innovative Partnership with Bellicum
Leading Innovation in Engineered T-cell Therapy Innovative Partnership with Bellicum Staged collaboration to evaluate Bellicum’s “GoTCR” switch technology Technology could complement our next generation efforts Provides potential on/off switch to T-cell May further enhance SPEAR T-cell proliferation
Slide 22: Allogeneic Approach to TCR T-cell Therapy
Leading Innovation in Engineered T-cell Therapy Allogeneic Approach to TCR T-cell Therapy Partnered with Universal Cells Benefits of allogeneic approach include Progenitor cell line evaluated; T-cell differentiation ongoing Pre-IND meeting in planning Allows one manufacturing batch to treat numerous
Slide 23: Global Technology Network: Partnering with Industry Leaders
Global Technology Network: Partnering with Industry Leaders Manufacturing Platform development Clinical 24
Slide 24: Optimizing T-cell Product Manufacturing
Optimizing T-cell Product Manufacturing 25
Slide 25: Advantages of Adaptimmune's Manufacturing Process
Advantages of Adaptimmune’s Manufacturing Process Robust Expansion Maximum Flexibility Positive Selection Serum Free Expansion Rapid Turnaround T-cell Persistence Minimizes vector requirement, no IL-2 or feeder cells Cryopreservation possible on both ends of the manufacturing process CD3/CD28 beads;
Slide 26: Cell Manufacturing: Improved Efficiency over Academic Process
Freeze apheresis (process improved to freeze on both ends) Isolation and T-cell stimulation with CD3/CD28 beads (no elution or CD25 depletion required) Extended expansion time Optimized serum-free expansion and harvest 27 Cell Manufacturing Improved Efficiency over Academic Process
Slide 27: Cell Manufacturing: Improved Efficiency over Academic Process
Cell Manufacturing Improved Efficiency over Academic Process Isolation and T-cell, Optimized Freeze a stimulation with Extended serum-free apheresis CD3/CD28 beads expansion time expansion and (process improved to freeze on both ends) Coe harvest depletion required) 3% Adaptimmune e
Slide 28: Strong Financial Position
Strong Financial Position * Total liquidity position is a non GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP ** Guidance excludes any new business development and is based on current company assumptions Fi
Slide 29: 2017: A Year of Significant Data Delivery
2017: A Year of Significant Data Delivery Potential for Data from Multiple SPEAR T-cell Therapies in 2017 and 2018 NY-ESO Synovial Sarcoma Cohorts 1, 2, and 4 MRCLS Multiple Myeloma + KEYTRUDA Ovarian + Flu NSCLC MAGE-A10 NSCLC Urothelial (bladder), melanoma, H&N MAGE-A4 Urothelial, melanoma, H&N, o
Slide 30: March 2017
March 2017 Corporate Presentation
Slide 31: March 2017
March 2017 Corporate Presentation & Adaptimmune NSFORMING TCELL THERAPY
Adaptimmune Therapeutics — Investor Presentation (March 2017) on 6ix